Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 13/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 13/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 12/20 | 1.00 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.30 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.30 |
| ▸ | SCD | O00767 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL747366 | 0.74 | SLC6A2 (0.72) | SLC6A2SLC6A4SLC6A3ADCY5 | |
| SCHEMBL1246525 | 0.74 | SLC6A2 (0.58) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1247430 | 0.73 | SLC6A2 (0.62) | SLC6A2SLC6A4SLC6A3SCD | |
| SCHEMBL29641649 | 0.71 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL28612780 | 0.71 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL750707 | 0.71 | SLC6A2 (0.64) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1247946 | 0.69 | SLC6A2 (0.53) | SLC6A2SLC6A4SLC6A3KDM1A | |
| SCHEMBL1247368 | 0.68 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL10000239 | 0.67 | NPC1 (0.53) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL17051572 | 0.66 | NPC1 (0.52) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9604960-B2 | Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9034899-B2 | Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-20150126517-A1 | ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF | APOLLO ADMINISTRATIVE AGENCY LLC, AS SUCCESSOR AGENT | 2015-05-07 | — | — | US | disclosed |
| EP-2429295-B1 | ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF | ALBANY MOLECULAR RES INC (US) | 2013-12-25 | — | — | EP | disclosed |
| EP-2429295-A1 | ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF | Albany Molecular Research, Inc. (US) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010132437-A1 | ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292242-A1 | ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292242-A1 | ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF | NLN, HTR3B, HTR2C | SLC6A2 64/4885SLC6A4 98/4885SLC6A3 87/4885 |
| US-20150126517-A1 | ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF | NLN, HTR3B, HTR2C | SLC6A2 64/4885SLC6A4 98/4885SLC6A3 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.